The Journal of Medical Microbiology, Vol 30, Issue 3 219-226, Copyright © 1989 by Society for General Microbiology

JOURNAL ARTICLE

Production and characterisation of monoclonal antibodies to Verotoxins 1 and 2 from Escherichia coli of serotype O 157:H7

V. V. Padhye, T. Zhao and M. P. Doyle
Department of Food Microbiology and Toxicology, University of Wisconsin-Madison 53706.

Fourteen hybridoma cell lines were isolated that produced monoclonal antibodies (MAbs) to purified Verotoxins 1 and 2 (VT1, VT2) of Escherichia coli of serotype O157:H7. Of these MAbs, eight were obtained by immunisation of BALB/c mice with purified VT1, and six were obtained from BALB/c mice immunised with purified VT2. With the exception of MAb 1C5, with a heavy chain of IgG2b class, antibodies produced from mice immunised with heat-treated toxin were of IgM class. MAbs produced from mice immunised with heat-treated VT1 or VT2 reacted with both verotoxins in ELISA, and Western-blot analysis revealed that they reacted with subunit A and the A1 fragment of nicked subunit A of both toxins, but not with subunit B; furthermore, none of them neutralised Vero cytotoxicity or mouse lethality of either toxin. In contrast, MAbs produced from mice immunised with heat-treated and formalin-treated VT1 reacted in Western blots with subunits A and B of VT1 and subunit A, but not subunit B, of VT2, reacted in ELISA with VT1 only, and neutralised Vero cytotoxicity and mouse lethality of VT1 but not of VT2. Results indicate the existence of a common epitope on subunit A of VT1 and VT2 that is not responsible for the biological activity of these toxins, and that subunit B is essential for the biological activity of VT1. MAbs capable of reacting with both verotoxins from E. coli of serotype O157:H7 may be useful reagents for screening bacterial isolates capable of producing one or both of these toxins.

This article has been cited by other articles:

				S. X. Wen, L. D. Teel, N. A. Judge, and A. D. O'Brien A plant-based oral vaccine to protect against systemic intoxication by Shiga toxin type 2 PNAS, May 2, 2006; 103(18): 7082 - 7087. [Abstract] [Full Text] [PDF]

				A. S. Sheoran, S. Chapman-Bonofiglio, B. R. Harvey, J. Mukherjee, G. Georgiou, A. Donohue-Rolfe, and S. Tzipori Human Antibody against Shiga Toxin 2 Administered to Piglets after the Onset of Diarrhea Due to Escherichia coli O157:H7 Prevents Fatal Systemic Complications Infect. Immun., August 1, 2005; 73(8): 4607 - 4613. [Abstract] [Full Text] [PDF]

				D. E. Akiyoshi, C. M. Rich, S. O'Sullivan-Murphy, L. Richard, J. Dilo, A. Donohue-Rolfe, A. S. Sheoran, S. Chapman-Bonofiglio, and S. Tzipori Characterization of a Human Monoclonal Antibody against Shiga Toxin 2 Expressed in Chinese Hamster Ovary Cells Infect. Immun., July 1, 2005; 73(7): 4054 - 4061. [Abstract] [Full Text] [PDF]

				S. Tzipori, A. Sheoran, D. Akiyoshi, A. Donohue-Rolfe, and H. Trachtman Antibody Therapy in the Management of Shiga Toxin-Induced Hemolytic Uremic Syndrome Clin. Microbiol. Rev., October 1, 2004; 17(4): 926 - 941. [Abstract] [Full Text] [PDF]

				A. S. Sheoran, S. Chapman, P. Singh, A. Donohue-Rolfe, and S. Tzipori Stx2-Specific Human Monoclonal Antibodies Protect Mice against Lethal Infection with Escherichia coli Expressing Stx2 Variants Infect. Immun., June 1, 2003; 71(6): 3125 - 3130. [Abstract] [Full Text] [PDF]

				J. Mukherjee, K. Chios, D. Fishwild, D. Hudson, S. O'Donnell, S. M. Rich, A. Donohue-Rolfe, and S. Tzipori Production and Characterization of Protective Human Antibodies against Shiga Toxin 1 Infect. Immun., October 1, 2002; 70(10): 5896 - 5899. [Abstract] [Full Text] [PDF]

				J. Mukherjee, K. Chios, D. Fishwild, D. Hudson, S. O'Donnell, S. M. Rich, A. Donohue-Rolfe, and S. Tzipori Human Stx2-Specific Monoclonal Antibodies Prevent Systemic Complications of Escherichia coli O157:H7 Infection Infect. Immun., February 1, 2002; 70(2): 612 - 619. [Abstract] [Full Text] [PDF]

				D. Karpman, D. Papadopoulou, K. Nilsson, A.-C. Sjogren, C. Mikaelsson, and S. Lethagen Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome Blood, May 15, 2001; 97(10): 3100 - 3108. [Abstract] [Full Text] [PDF]

				H. Nakao, N. Kiyokawa, J. Fujimoto, S. Yamasaki, and T. Takeda Monoclonal Antibody to Shiga Toxin 2 Which Blocks Receptor Binding and Neutralizes Cytotoxicity Infect. Immun., November 1, 1999; 67(11): 5717 - 5722. [Abstract] [Full Text] [PDF]